Journal of International Translational Medicine
Citation Search Quick Search Adv Search
Home       Introduction       Editorial Board       Current Issue        Subscribe       Online Publication       About us
Journal of International Translational Medicine
Journal of International Translational Medicine
JITM, ISSN 2227-6394
founded in 2012
Editor-in-chief:Feng Jifeng, China
Open Access
  Instruction for authors
  Online Submission
  Author Guideline
  General Policy
  Copyright Transfer
   Statement
 Conflict of interest
  Disclaimer
  The types of manuscript
  Requirements for
   manuscripts
 
  Reviewing Center
  Peer Review Policy
  Peer Review login
  Editor Work login
  Office Work login
  Editor-in-Chief login
 
  Online Journal
  Accepted
  Online First
 Current Issue
  Archive
  Most Read
  Most Download
  Email Alert
 
  Current Issue
 
2018 Vol. 6, No. 1
Published: 01 April 2018

 
Select | Export to Abstract
       

Preparation Before the Administration of Dara

Qi WANG
Journal of International Translational Medicine, 2018, 6(1): 1-2 | doi:10.11910/2227-6394.2018.06.01.01
Full Text: PDF (770 KB)    
Show Abstract
       

Meta analysis of Clinical Efficacy of Traditional Chinese Medicine in the Treatment of Aplastic Anemia Hot!

Le-min XIA, Le-le CUI, Yi-ling JIANG, Zheng QIN, Mei-hong LUO
Journal of International Translational Medicine, 2018, 6(1): 3-7 | doi:10.11910/2227-6394.2018.06.01.02
Full Text: PDF (1111 KB)    
Show Abstract

Objective: To evaluate the clinical efficacy of traditional Chinese medicine (TCM) in treatment of aplastic anemia (AA), providing evidence for the development of TCM diagnosis and treatment guidelines of AA therapy.
Methods: Randomized or semi-randomized control trials of AA treatments with TCM were retrieved, and the selected literatures were scored with Jadad scale. The data were extracted, and RevMan 5.2.6 software was used for meta analysis.
Results: Two studies on AA treatment with Liuwei Dihuang pills combined with compound Zaofan pill were included. The results of meta analysis showed that there were no statistical significant differences in total efficiency between Liuwei Dihuang pills combined with compound Zaofan pill and androgen in the treatment of AA (P = 0.65). However, adverse reactions including liver damage and masculinization of women in the former treatment of AA, were lighter than the latter (P < 0.05). other researches on the treatment of AA with TCM were lack of clinical trials reports.
Conclusions: TCM had certain curative effect in the treatment of AA. However, the quality of literature was generally low and the sample size was small, which made the validation of the results poor. Therefore, more researches with high quality were still needed to provide high level evidence.

       

Feng QI, Yu-xiao ZHENG, Jian-zhong ZHANG, Hong CHENG, Shu-hui SI, Dong-li
Journal of International Translational Medicine, 2018, 6(1): 8-15 | doi:10.11910/2227-6394.2018.06.01.03
Full Text: PDF (1247 KB)    
Show Abstract
Objects: To compare the safety and clinical efficacy of selective clamping and hilar clamping during minimally invasive partial nephrectomy.
Methods: Relevant studies were searched from the databases PubMed, EMBASE, and Web of Science till 1st October 2017. Crude odds ratios (ORs) or standardized mean differences (SMD) with 95% confidence intervals (CIs) were calculated to evaluate the strength of associations. Bagg’s funnel plots and Egger’s regression test were used to evaluate publication bias.
Results: A total of 9 relevant studies including 1576 patients were enrolled in this meta-analysis. Totally, selective clamping group had significantly greater estimated blood loss (SMD = 0.28, 95% CI: 0.15-0.42) than hilar clamping group, while no statistical differences were detected in operative time (SMD = -0.02, 95% CI: -0.33-0.29), warm ischemia time (SMD = -0.12, 95% CI: -0.61-0.38), and length of stay (SMD = -0.03, 95% CI: -0.26-0.20) between two groups. Moreover, we found no significant differences between two groups in overall complications (OR = 0.86, 95% CI: 0.60-1.22), positive surgical margins (OR = 1.47, 95% CI: 0.54-3.96), urinary leakage (OR = 2.48, 95% CI: 0.64-9.70) and blood transfusion (OR = 1.10, 95% CI: 0.37-3.28). In the aspect of renal function (one week after surgery), selective clamping group indicated better renal function with lower change and lower percent change in glomerular filtration rate (SMD = 0.72, 95% CI: 0.34-1.10; SMD = 0.76, 95% CI:0.56-0.96, respectively). However, renal function between two groups emerged no obvious difference in 3-month and 6-month follow-up (SMD = -0.00, 95% CI = -0.68-0.67; SMD = 0.52, 95% CI: -0.15-1.20, respectively).
Conclusion: Comparing with hilar clamping, selective clamping showed better short-term postoperative renal function, along with more estimated blood loss. More comprehensive studies with longer follow-up are required in the future.


       

Zhiqiang QIN, Feng WANG, Haoxiang XU, Lingyan XU, Ran LI, Lei ZHANG, Jianxin LI
Journal of International Translational Medicine, 2018, 6(1): 16-24 | doi:10.11910/2227-6394.2018.06.01.04
Full Text: PDF (1535 KB)    
Show Abstract
Background: MiRNA-141 has been shown to play an important role in cancer formation and progression. However, the prognostic significance of miRNA-141 expression in human cancers remained contradictory. Thus, we carried out a meta-analysis of 26 relevant studies to investigate the prognostic value of miRNA-141 expression in multiple human malignancies.
Methods: Eligible studies were searched in the online databases PubMed, Embase and Web of Science up to December 1st, 2017. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to investigate the association between high miRNA-141 and the prognosis of cancer.
Results: In total, 26 eligible studies were included in this meta-analysis. Our results showed that high miRNA-141 expression was significantly associated with a poor overall survival (OS) (pooled HR = 1.51, 95% CI: 1.10-2.09), but has no significant association with progression-free survival (PFS)/disease-free survival (DFS)/disease-specific survival (DSS) (pooled HR =1.04, 95% CI: 0.82-1.34). Furthermore, in the term of OS, when stratified by ethnicity, increased miRNA-141 expression was significantly associated with unfavorable OS only in Asians (pooled HR = 1.58, 95% CI: 1.01-2.49). Moreover, in the subgroup analysis by detected sample, the results were significant only in Blood subgroup (pooled HR = 2.37, 95% CI: 1.18-4.75).
Conclusions: Our results demonstrated high miRNA-141 expression was better at predicting patient survival rather than disease progression for malignant tumors, especially in Asians. Considering the relative insufficiency of studies, more studies and further investigations were needed in the future.
       

Hot!
Hong CHENG, Shuhui SI,Yu-xiao ZHENG, Jian-zhong ZHANG, Feng QI, Dong-liang CAO, Chuan-jie ZHANG, Gui-ya JIANG, Si SUN, Xin-wei WANG
Journal of International Translational Medicine, 2018, 6(1): 25-33 | doi:10.11910/2227-6394.2018.06.01.05
Full Text: PDF (1535 KB)    
Show Abstract
Objective: To compare the outcomes of enhanced recovery after surgery (ERAS) and standard Care (SC) after radical cystectomy.
Methods: PubMed, Embase, Web ofScience, Medline and the Cochrane Library were searched to identify relevant studies, and the last update was up to till October 2017 according to the preferred reporting items for systematic review and meta-analysis (PRISMA). Twenty studies were suitable for inclusion criteria. Risk ratios (RRs) or standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) were used to assess the effects of ERAS or SC calculated. Relevant outcomes were compared. We used contour-enhanced funnel plots and Harbord modificationof the Egger test to assess the publication bias.
Results: We observed a lower overall complication rate (RR:0.86, 95% CI: 0.79-0.93, P = 0.502, I 2 = 0%), a shorter LOS (SMD: -1.02, 95% CI: -1.52 to -0.53, P = 0.000, I 2 =96.7%), and a faster recovery of bowel function (SMD: -1.13, 95% CI: -1.73 to-0.53, P = 0.000, I 2 = 95.1%) in the ERAS group after cystectomy. There was no differencesin the 90-d readmission rates (RR: 1.00, 95% CI: 0.82-1.21, P = 0.238, I 2 = 26.2%) and 30-dreadmission rate inthe ERAS group (RR: 0.78, 95% CI: 0.52-1.16, P = 0.075, I 2= 45.7%). Moreover, no significant differences were found regardingEBL (SMD:-0.11, 95% CI: -0.39-0.17, P = 0.462, I 2 = 0%), number of lymph nodes removed rate (SMD: 0.06, 95% CI: -0.18-0.30, P = 0.232, I 2 = 31.5%) and transfusion rate (RR: 0.89, 95% CI: 0.74-1.07, P = 0.958, I 2 = 0%).
Conclusions: ERAS protocols might reduce LOS, time-to-bowel function, and rateof overall complications after cystectomy.


       

Hot!
Yu-xiao ZHENG, Zhi-qiang QIN, Feng WANG, Jian-zhong ZHANG, Hong CHENG, Shu-hui SI, Hao-xiang XU, Yi WANG, Xiang ZHOU, Xiao LI, Jian-xin XUE
Journal of International Translational Medicine, 2018, 6(1): 34-44 | doi:10.11910/2227-6394.2018.06.01.06
Full Text: PDF (809 KB)    
Show Abstract
Objective: The strategy of androgen deprivation therapy (ADT) applied in patients with prostate cancer (PCa) to achieve optimal clinical and oncologic outcomes has been a longstanding debate. The objective of our study was to perform a meta-analysis to compare the efficacy, quality of life and adverse events profile of intermittent versus continuous androgen deprivation for prostate cancer.
Methods: We searched PubMed, EMBASE and Web of Science to extract the basic characteristics. Besides, data of endpoint such as overall survival (OS), rogression free survival (PFS), cancer-specific survival (CSS) and time to progression (TTP) as well as quality of life (QoL) were also collected. In addition, the results were expressed as hazard ratio (HR) with 95% confidence interval (CI).
Results: 17 articles including a total 6,733 patients with any stage of PCa were included in our review. No significant differences were found in PFS (HR = 0.93, 95% CI: 0.83-1.03), TTP (HR = 0.96, 95% CI: 0.84-1.07) between intermittent androgen deprivation (IAD) and continuous androgen deprivation (CAD), whereas CAD howed benefits associated with OS (HR = 0.92, 95% CI: 0.85-0.98) and CSS (HR = 0.86, 95% CI: 0.74-0.98). In addition, IAD might have a superior outcome ompared with CAD, especially in sexual functioning and headache favoring. Controversial outcomes were also seen in some aspects such as hot flushes, gynecomastia, breast pain or fatigue.
Conclusion: PFS and TTP were similar between IAD and CAD, whereas CAD showed benefits associated with OS and CSS. IAD might have benefits in QoL and have less adverse effects, especially in sexual dysfunction and headache.
       

Hot!
Wei-zhang XU, Xiao LI, Yang WU, Zhi-qiang QIN, Zhifei MA, Wenjia XIA, Si-wei WANG, Ya-jie YU, Jie XU, Rong YIN
Journal of International Translational Medicine, 2018, 6(1): 45-54 | doi:10.11910/2227-6394.2018.06.01.07
Full Text: PDF (1372 KB)    
Show Abstract
The relationship between CYP17 rs743572 polymorphism and the risk of prostate cancer (PCa) remained inconclusive. This meta-analysis was therefore performed to systematically evaluate such association. Eligible studies were retrieved by searching PubMed, Embase and Web of Science with the last search till October 31, 2017 The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. Trial sequential analysis was utilized to
reduce the risk of type I error and estimate whether the evidence of the results was sufficient. Overall, there was no significant association between CYP17 rs743572 polymorphism and PCa risk (OR = 0.98; 95% CI: 0.86 - 1.11 for A2/A2 vs. A1/A1; OR =1.00; 95% CI: 0.92-1.09 for A1/A2 vs. A1/A1; OR = 0.98; 95% CI: 0.88-1.09 for A2/A2 vs. A1/A2+A1/A1; OR = 1.00; 95% CI:0.91-1.09 for A1/A2+A2/A2 vs. A1/A1; OR = 1.00; 95% CI: 0.93-1.06 for A2 vs. A1). In the stratified analysis by ethnicity, in
African population who carried the rs743572 polymorphism under A2A2 versus A1A1 (OR = 1.34, 95% CI: 1.03-1.73, P = 0.759, I 2 = 0.0%), A2A2 + A1A2 versus A1A1 (OR = 1.35, 95% CI: 1.05-1.72, P = 0.606, I 2 = 0.0%) and A1 versus A2 (OR = 1.22, 95%CI: 1.02-1.46, P = 0.516, I 2  = 0.0%) genetic models had an increased risk of prostate cancers. However, when stratified by source of control, sample size and genotyping method, no significant associations were observed. Furthermore, the trial sequential analysis was utilized, and the results validated findings of the current meta-analysis. Thus, this meta-analysis suggested CYP17 rs743572 polymorphism might have connection with PCa susceptibility in African ethnicity.
 
 
Chinese Editorial Department, Journal of International Translational Medicine (English Edition)
Address: Room 201, 203, 205, No.3 Building, Zijin Lianhe Cubic Square, Nanjing, 210037, China
Website:www.jitm.hk E-mail:jitm2012@jitm.hk;TEL:+86-025-85552880,-86- 4000600047